Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half‐side comparison analysis

Durand, Frédérick; Staumont, D.; Bonnevalle, A.; Hachulla, É.; Hatron, P.Y.; Thomas, Philip

doi:10.1111/j.1600-0781.2007.00308.x

Cited by 29 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the aforementioned results, the data of Durand et al (45), which was based on a controlled investigation, suggest that UV-A1 therapy is ineffective in acrosclerosis (45). Otherwise one must consider a systemic UV-A1 effect that could explain the results of Durand et al (45).…”

Section: Introductionmentioning

confidence: 86%

“…Hence, this study also demonstrated that UV-A1 treatment is effective in SSc patients, particularly for acrosclerosis (44). In contrast, Durand et al (45) reported a randomized observer-blinded half-side controlled trial on UV-A1 treatment of acrosclerosis. They used low-dose UV-A1 (40 J/cm 2 ) three times per week (14 weeks treatment period).…”

Section: Introductionmentioning

confidence: 99%

“…Otherwise one must consider a systemic UV-A1 effect that could explain the results of Durand et al (45). Moreover, Tewari et al reported medium-dose UV-A1-induced reduction of microstomia in a SSc patient (46).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Gambichler

Schmitz

2018

Front. Med.

View full text Add to dashboard Cite

In this article we describe efficacy and safety aspects of ultraviolet A1 (UV-A1) phototherapy in fibrosing conditions. UV-A1 is a specific phototherapeutic modality that is defined by a selective spectral range (340–400 nm). UV-A1 includes distinct modes of action qualifying this method for therapy of a variety of conditions, in particular fibrosing skin diseases. Concerning efficacy of UV-A1 phototherapy in fibrosing conditions, the best evidence obtained from randomized controlled trials exists for localized scleroderma. Moreover, fibrosing disorders such as lichen sclerosus and graft-vs.-host disease can be treated successfully by means of UV- A1. Regarding the optimal dosage regimen medium-dose UV-A1 seems to be linked to the best benefit/risk ratio. Possible acute adverse events of UV-A1 phototherapy include erythema and provocation of photodermatoses. Skin ageing and skin cancer formation belong to the chronic adverse events that may occur after long-term UV-A1 phototherapy.

show abstract

Section: Introductionmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Gambichler

Schmitz

2018

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Moreover, patients evaluated the skin pigmentation on the VAS (–50 mm, extremely depigmented; 0 mm, unchanged; +50 mm, extremely hyperpigmented) and efficacy of therapy (–50 mm, extreme worsening; 0 mm, unchanged; +50 mm, extreme improvement) before and after 1, 2, 3 and 4 weeks of irradiation and in the follow-up weeks 5 and 6. In several previous publications, VAS have been evaluated for their efficacy in determining different levels of cosmetic outcome or degrees of clinical improvement in dermatology [13,14,15]. Photographs of both the irradiated plaque and of the control plaque were taken every week.…”

Section: Methodsmentioning

confidence: 99%

Prospective Randomized Study on the Efficacy of Blue Light in the Treatment of Psoriasis Vulgaris

et al. 2011

View full text Add to dashboard Cite

Background:Blue light has no known toxic effects on human skin, but reduces the proliferative capacity of keratinocytes in vitro. We therefore investigated the efficacy of blue light in the treatment of psoriasis vulgaris (PV). Methods: Forty patients with mild to moderate PV and bilateral plaques were assigned to two groups. Group 1 (n = 20) received irradiation at home with blue light (light-emitting diode, LED, emission maximum: 420 nm) once daily for 4 weeks. In parallel, group 2 (n = 20) performed irradiations with another blue light device (LED emission maximum: 453 nm). The contralateral control plaques remained untreated in both groups. Results: Thirty-seven patients completed the trial. The main study parameter, the difference of Local Psoriasis Severity Index (LPSI) scores of the irradiated plaques compared to the control plaques, showed statistically significant improvement after 4 weeks of treatment in both groups [group 1 (420 nm): n = 17, p = 0.04; group 2 (453 nm): n = 20, p = 0.04]. Accordingly, plaque status as assessed by both the physicians and the patients improved continuously during the 4 weeks of treatment and steadily declined thereafter. Conclusion: Blue light appears to be a promising treatment modality in PV that warrants further evaluation in larger studies.

show abstract

“…Marked softening was noted in all four patients and there was a significant increase in joint passive range of motion, skin temperature and cutaneous elasticity (all with p values < 0.05). By contrast, a randomized, investigator-blinded study conducted by Durand et al with half-side comparison analysis in nine patients who received low-dose UVA1 (40 J/cm 2 three times per week for 14 weeks) phototherapy to one hand, demonstrated similar improvement in both hands as measured by the MRSS [41]. Moreover, no changes were evident regarding the index of flexion and extension in these patients (although two patients did note improved function in the treated hand).…”

Section: Systemic Sclerosis (Scleroderma)mentioning

confidence: 90%